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Abstract
A commentary in Nature entitled "Towards responsible use of cognitive-enhancing drugs by the
healthy" (Greely et al 2008 Nature 456: 702–705) offers an opportunity to move toward a humane
societal appreciation of mind-altering drugs. Using cognitive enhancing drugs as an exemplar, this
article presents a series of hypotheses concerning how an individual might learn optimal use. The
essence of the proposal is that individuals can cultivate sensitivity to the effects of ever-smaller
amounts of psychoactive drugs thereby making harm less likely and benign effects more probable.
Four interrelated hypotheses are presented and briefly discussed. 1. Humans can learn to
discriminate ever-smaller doses of at least some mind-altering drugs; a learning program can be
designed or discovered that will have this outcome. 2. The skill to discriminate drugs and dose can
be generalized, i.e. if learned with one drug a second one is easier and so on. 3. Cultivating this skill/
knack would be beneficial in leading to choices informed by a more accurate sense of mind-body
interactions. 4. From a philosophical point of view learning the effects of ever-smaller doses of
psychoactive agents offers a novel path into and to transcend the objective/subjective barrier and
the mind/body problem.
Whatever the fate of these specific hypotheses, discussion of cognitive enhancing drugs for healthy
individuals has the potential to inspire innovative educational and public policy initiatives toward all
types of mind-altering drugs and the people who use them.
Commentary
A commentary in Nature advocates the availability of cog-
nitive enhancing pharmaceuticals for healthy individuals
[1].
Howard Gardner makes a strong [2] but controversial [3]
case that human intelligence is most accurately described
as a set of several distinct and independent intelligences.
Independence implies there is no a priori reason to expect
that a single pharmacology would enhance all forms of
intelligence. Indeed a drug might enhance a particular
type of intelligence while diminishing others.
Untoward effects are a fact of pharmacology. They are
likely to be subtle, individual, difficult to anticipate, and
important for drugs that modify the mind. New ways of
thinking about the cost-benefit ratio are needed. Because
the mind is subtle and individual, the cost-benefit ratio is
likely to vary on an individual basis.
Cognitive enhancing drugs intended for healthy people
ought to be drugs of choice. Informed free will is the eth-
ical, and should be the practical, basis for decisions
regarding their use. The cost-benefit ratio for these drugs
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comes down to a personal choice but one that can be
informed.
Informing free will in this case means allowing and facili-
tating individual awareness of how a drug interacts with
his/her mind. Effects and side effects are likely to be indi-
vidual and need to be appreciated individually in order to
facilitate choices. Both objective measures of intelli-
gence(s) and subjective experience are important.
William James advocated introspection as an essential
aspect of psychological research [4] including the effects
of alcohol and nitrous oxide [5]. Introspection has largely
been supplanted by objective and operational methods in
most of psychology, but its resurgence would be especially
timely in the context of intelligence enhancing drugs and
harm reduction broadly interpreted. Introspection would
seem an essential aspect of informing free will in the case
of voluntary consumption of cognitive enhancing drugs
by healthy individuals. The question becomes how to
introspect optimally with respect to psychoactive drugs.
Introspection in this context is pragmatically defined as an
individual's subjective process to seek understanding of
their mind and body. Pharmacology is objective and the
interface would have both aspects. Whatever someone
does to try and sense the drug- whether it be sitting cross
legged on a cushion with their eyes closed, monitoring
their breath, or running up and down stairs- the efficacy
of the process would be objective: What is the smallest
amount of drug that they can discern and can they learn
to increase their discernment?
Below are several related hypotheses concerning intro-
spection and how it might be improved as a tool for
healthy individuals to appreciate the effects of intelligence
enhancing pharmaceuticals. The overall supposition is
that the best choices concerning the voluntary consump-
tion of mind-altering drugs will be made by those individ-
uals who are best able to assess what particular drugs- and
there is sure to be a wide choice of alternatives- are doing
to their minds. The working hypotheses below are offered
in a pragmatic spirit.
The core hypothesis is the optimistic expectation that the
nervous system and consciousness have the potential to
be self-referential in an accurate and positive manner.
Undoubtedly, delusion and addiction are possible and
known to be potential problems with respect to drugs that
alter the mind. Having said that, it is reasonable to enter-
tain the hypothesis that the mind can inform as well as
fool itself. Introspection is a name for processes whereby
the mind of an individual reflects on and assesses itself. If
the optimistic hypothesis is accepted, then a further
hypothesis is that all introspection is not equal and some
modes of introspection are better than others. A further
hypothesis is that enhancement and education of intro-
spection is possible.
If it is possible to enhance pharmacological introspection,
there is a field of research awaiting development to
enhance and cultivate introspection directed toward
understanding what drugs do to an individual's mind.
More specific and guided forms of introspection and self
observation could be proposed and would take the form
of further specific hypotheses.
As an example I present the informal communication of a
colleague regarding her experience with Insight Medita-
tion [6] and the prescription drugs Xanax, Ativan, and
Paxil. "The meditation practice was largely following my
breath. I could feel my breath change when I was anxious.
With the drug I was less anxious and this was reflected in
my breathing. I lowered the dose of the drug over time
and found that I was able to do the same thing to my
breathing with less and less drug. Eventually I stopped
taking the drug and am now able to simulate the drug's
effect in my breathing and mind. However, there is a dif-
ference in my experience because when I was taking the
drug I was much less aware of my body. It was as if my
mind and body were separated. Now when I have an emo-
tion I feel something in my body."
Although three drugs were mentioned she reported that it
was primarily Paxil from which she reported quantita-
tively "weaning" herself with the aid of meditation prac-
tice. She herself suggested that her practice was akin to
cultivating a placebo effect. A key distinction is that a pla-
cebo effect is based on deception [7,8] whereas her prac-
tice is the opposite: I.e. a critical examination of what the
drugs do in her mind and a conscious mimicking of their
effects as mediated through the breath.
Another informal respondent reported that he liked to
ingest ca 50 mg methamphetamine once a month or so
"Just to know how good- including how smart- you can
feel". He apparently was not dependent on the drug but
was using what he considered to be his drug-enhanced
state as a benchmark, an internal role model, for how he
wanted to feel and function.
These anecdotal examples suggest experimental method-
ologies that could lead to results that would either support
or disprove the hypotheses. Volunteers would assimilate
(ingest or via intravenous catheter) small and then
increasing amounts of a mind-altering drug in a blinded
manner. Each dose or placebo would be followed by a
"sensing" period during which the subject would indicate
whether or not they believe they sense the drug. A mini-
mum dose that can be unambiguously sensed would beHarm Reduction Journal 2009, 6:10 http://www.harmreductionjournal.com/content/6/1/10
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established. After a sufficient wash out period (hours or
days) the test would be repeated. The question would be
after e.g. 10 repetitions of the test would the experimental
subject's threshold sensitivity for the drug be less than it
was at the start? The subject would be encouraged and per-
haps rewarded for every decrease in detection threshold.
Numerous variants of the experimental protocol are con-
ceivable and reasonable. For example, the first bolus
might be large enough to assure a sensation and the
threshold approached from above rather than from
below. Training sessions might be unblinded in order for
subjects to learn with certainty their internal sensation in
response to ever-smaller doses of the drug.
Howard Gardner's distinct types of intelligence may or
may not correspond to distinct classes of pharmacology.
For example, Ritalin might improve an individual's ability
to focus on a written exam and do math problems while
diminishing his or her ability to draw on another sort of
intelligence that enables him or her to do stand up com-
edy routines.
If the metaphor of a computer is applied to the mind then
introspection becomes an algorithm subject to optimiza-
tion. From the point of view of control theory as applied
to the brain, the relationship between perception and
response might place perception [9] and memory "out-
side" some sort of "central processor". By hypothesis, that
placement is arbitrary and the brain has the potential to
become skilled at perceiving changes in its internal state as
it is altered by pharmacology.
The interface of introspection with objective pharmaco-
logical criteria is a bridge across the objective versus sub-
jective dichotomy. Philosophical issues about the brain,
mind and body are exciting [10] but the possibility of a
new experimental program that can be refined through
cycles of experiment and hypothesis formation seems
uniquely valuable. The motivating hypotheses are that it
is possible to improve self-understanding of pharmaco-
logical effects on one's brain, that this will involve cultiva-
tion of a generalized skill, and that the acquisition of this
skill will be useful in the context of harm reduction. The
experimental methods would involve training and testing
of pharmacological sensitivity and its change over time.
The relationship between the hypothetical effect of sensi-
tivity induced by introspection and the literature on sen-
sitization [11] remains to be determined. An optimistic
hypothesis is that acquiring an introspective skill for the
effects of pharmacology will allow for desired and benign
effects at lower doses. Detrimental effects including toler-
ance, addiction, anxiety and psychomotor agitation are
differentially associated with higher doses and will
thereby be diminished.
Consider the possibility of a drug that enhances introspec-
tion. Might there be drugs that increase the mind's percep-
tion of what drugs are doing to it? The hypothesized drug
would increase the self-referential qualities of the nervous
system. "Pay attention to attention." [12]
A specific hypothesis is that introspective education with
respect to psychopharmacology will begin with training
the mind to recognize diminishing quantities of a drug. By
hypothesis, this is a general skill that can be learned
whose enhancement will inform decision-making with
regard to many drugs. Learning to become more sensitive
is not expected in the context of pharmaceutical models
that emphasize tolerance and addiction. On the other
hand, in learning, increasing the subtlety of pattern appre-
hension is expected. Therefore it is a valid research ques-
tion to ask which pharmaceuticals under what conditions
fall under the addiction or under the learning model.
Can humans learn to discriminate the effects on their
mind of smaller and smaller quantities of caffeine and/or
alcohol? If one learns to better sense one change does that
improve sensitivity to others? How improved and gener-
alized could such skills of increased discrimination
become? Introspection as outlined here is related to the
current literature of drug discrimination (e.g [13]). These
animal and human approaches are currently used to clas-
sify drugs as high or low potential for abuse. The cultiva-
tion of introspective skills that inform free will could
become the central pillar of an education program based
on a learning paradigm. The testable hypothesis is that a
learning paradigm is possible and can be based on
enhanced sensitivity to pharmacological effects.
Preceding the present and soon-arriving eras of intelli-
gence enhancing drugs was the psychedelic era of "con-
sciousness expanding" drugs. Clearly some things went
wrong. The pitfalls of this era should be studied with the
hope that they not be repeated. Three aspects deserve con-
sideration: 1) Criminalization 2) Trivialization 3) Evan-
gelical enthusiasm.
There are hints in the literature suggesting that some expe-
rienced users of psychedelics tended toward lower doses.
An interesting article "Some notes concerning dosage lev-
els of psychedelic compounds for psychotherapeutic
experiences" [14] contains the following passage that
implies learning the use of lower doses is possible, appro-
priate and often occurs without a specific instructional or
theoretical background.
Use of small dosages with experienced subjects
This writer has often noted that experienced subjects
tend to restrict themselves to a dosage level that theyHarm Reduction Journal 2009, 6:10 http://www.harmreductionjournal.com/content/6/1/10
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have found will induce a psychedelic experience. It is
our opinion that this level is often unnecessarily high
and we suggest that experienced individuals experi-
ment with smaller dosages. It is common experience
that a subject finds he needs a smaller amount of
material to induce a psychedelic experience after he
has had a few experiences with the larger dosage levels.
However, individuals will often continue to use dos-
ages of from 100 to 200 ug of LSD. It is hypothesized
that as dosage is decreased, variables of the environ-
ment and the clarity of mind prior to the session
become increasingly important. Consequently, prior
to small dosage sessions, a period of meditation is
highly useful to enable the individual to relax and to
clear his consciousness of irrelevancies. Dosages as
low as 10 ug to 25 ug LSD or one mg to two mg of psi-
locybin have been found to produce rather amazing
states of expanded consciousness.
The discussion of cognitive enhancing drugs tends to
assume that the effects will be temporary and that regular
consumption will be required to sustain an effect. Antici-
pating that mode of use raises the specter of dependence
and addiction. It is important to note that it is not the only
model for how drugs that alter intelligence might act. Vac-
cines are an example of a pharmaceutical for which a sin-
gle dose can yield benign consequences for a lifetime.
Consider the possibility of a single dose of a drug that
leads to life long consequences of increased intelligence.
To use or not use any particular drug to enhance the intel-
ligence of healthy individuals ought to be an informed
personal choice. An individual's appreciation of what the
drugs do to his/her mind enhances the ability to choose
wisely. Introspection has a place in informing free will
and leading toward optimum outcomes of the opportuni-
ties afforded by the availability of intelligence enhancing
drugs. Not all introspection is equal. A research program
would characterize introspective states that are optimally
sensitive to identifying the effects of drugs on the mind.
The experiences engendered by mind-altering drugs, as
well as the motivations for their use, are strongly influ-
enced by social and physical context [15,16]. There is not
a firm line between the proposed use of legal intelligence
enhancing drugs and the less legal use of drugs today.
Stimulants in particular overlap with some of the cogni-
tive enhancers. Functional users of methamphetamine
vary widely with regard to their skill in titrating dosage to
desired effect. Individual skill level at present may too
often be regarded as if it is a fixed parameter of individual
biology and/or socio-economic status rather than learna-
ble. This inference seems unnecessarily pessimistic. The
skill of riding a bicycle varies but is learned. The common
situation with mind-altering drugs is as if users are
popped onto their seats and pushed down a steep hill.
That is an unforgiving way to learn. In fact it is not a situ-
ation for learning but rather for selection of certain preex-
isting characteristics. Scoring under non-learning
conditions could explain why the skill level appears
innate and fixed.
An analogous possibility for confusion between purely
selective and learning-like processes arises in the study of
bacterial mutation [17]. Immediately lethal selection
allows only pre-existing mutants and in the absence of
confounding factors leads to Luria-Delbruck kinetics[18].
On the other hand, conditions that are stressful but do not
kill, at least in the short or medium term, allow bacteria
opportunities to respond physiologically and to mutate
genetically after the selection has been applied. The result-
ing adaptation under stress that is not immediately lethal
can lead to properties that appear akin to "learning".
Learning could radically alter the already complex rela-
tionship of gene-environment interactions. New interpre-
tations would become available to pharmacogenetics
with regard to mind-altering drugs[19,20]. At an arguably
extreme level of analogy, certain genes are key to the
human ability to learn language[21] yet there is no appar-
ent genetic specificity for one human language over
another.
If the hypotheses in this article turn out correct, i.e. if skills
of increased sensitivity to mind altering pharmacology
can be cultivated, further work would be needed to
explore their implications for drug use and abuse in differ-
ent situations and contexts. A bridge between the labora-
tory and the library or the street would include the effect
of context as well as internal state on the ability to judge
pharmacology and dose.
This article proposes a series of four interrelated hypothe-
ses that have the virtue of being subject to cycles of exper-
imental inquiry leading to potential falsification and
refinement: 1) Humans can learn to discriminate ever-
smaller doses of at least some mind-altering drugs. 2) Dis-
crimination skills generalize, i.e. once learned, discrimi-
nation will be easier with a second drug and so on. 3) This
skill/knack would be beneficial in informing individual
choices with more accurate sense of mind-body interac-
tions. 4) From a philosophical point of view learning the
effects of ever-smaller doses of psychoactive agents offers
a novel path into and to transcend the objective/subjec-
tive barrier and the mind/body problem.
Whatever the fate of these specific hypotheses, discussion
of cognitive enhancing drugs for healthy individuals has
the potential to inspire innovative educational and publicPublish with BioMed Central    and   every 
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policy initiatives toward all types of mind-altering drugs
and the people who use them.
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